CN101618208B - 含微粉化重组人血管内皮抑制素缓释微球的制备方法 - Google Patents
含微粉化重组人血管内皮抑制素缓释微球的制备方法 Download PDFInfo
- Publication number
- CN101618208B CN101618208B CN2008101227642A CN200810122764A CN101618208B CN 101618208 B CN101618208 B CN 101618208B CN 2008101227642 A CN2008101227642 A CN 2008101227642A CN 200810122764 A CN200810122764 A CN 200810122764A CN 101618208 B CN101618208 B CN 101618208B
- Authority
- CN
- China
- Prior art keywords
- recombinant human
- vascular endothelial
- human vascular
- endothelial inhibin
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 68
- 230000003511 endothelial effect Effects 0.000 title claims abstract description 57
- 239000000893 inhibin Substances 0.000 title claims abstract description 57
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 title claims abstract description 57
- 230000002792 vascular Effects 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 40
- 238000013268 sustained release Methods 0.000 title claims abstract description 7
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 7
- 239000003921 oil Substances 0.000 claims abstract description 24
- 235000019198 oils Nutrition 0.000 claims abstract description 23
- 239000003960 organic solvent Substances 0.000 claims abstract description 17
- 239000002480 mineral oil Substances 0.000 claims abstract description 14
- 235000010446 mineral oil Nutrition 0.000 claims abstract description 14
- 239000000725 suspension Substances 0.000 claims abstract description 14
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 14
- 239000008158 vegetable oil Substances 0.000 claims abstract description 14
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 12
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000003756 stirring Methods 0.000 claims abstract description 9
- 229960004275 glycolic acid Drugs 0.000 claims abstract description 8
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 239000004310 lactic acid Substances 0.000 claims abstract description 6
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 6
- 239000012982 microporous membrane Substances 0.000 claims abstract description 6
- 239000000839 emulsion Substances 0.000 claims abstract description 4
- 229920001577 copolymer Polymers 0.000 claims abstract description 3
- 239000006194 liquid suspension Substances 0.000 claims abstract description 3
- 102000002746 Inhibins Human genes 0.000 claims description 54
- 108010004250 Inhibins Proteins 0.000 claims description 54
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 27
- 238000004108 freeze drying Methods 0.000 claims description 21
- 108700008165 endostar Proteins 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- -1 sucrose ester Chemical class 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 239000000178 monomer Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 5
- 239000000787 lecithin Substances 0.000 claims description 5
- 229940067606 lecithin Drugs 0.000 claims description 5
- 235000010445 lecithin Nutrition 0.000 claims description 5
- 239000003208 petroleum Substances 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 4
- 229940057995 liquid paraffin Drugs 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000012460 protein solution Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 2
- 239000000337 buffer salt Substances 0.000 claims description 2
- 230000008021 deposition Effects 0.000 claims description 2
- 229940008099 dimethicone Drugs 0.000 claims description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 2
- 239000010419 fine particle Substances 0.000 claims description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 239000003814 drug Substances 0.000 description 25
- 229940079593 drug Drugs 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000003022 colostrum Anatomy 0.000 description 5
- 235000021277 colostrum Nutrition 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 5
- 238000000935 solvent evaporation Methods 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102400001047 Endostatin Human genes 0.000 description 3
- 108010079505 Endostatins Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011806 microball Substances 0.000 description 3
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010016076 Octreotide Proteins 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 2
- 239000008307 w/o/w-emulsion Substances 0.000 description 2
- 101500026378 Homo sapiens Endostatin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 108010089977 LXT-101 Proteins 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- NWGKJDSIEKMTRX-MDZDMXLPSA-N Sorbitan oleate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(O)C1OCC(O)C1O NWGKJDSIEKMTRX-MDZDMXLPSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000002474 gonadorelin antagonist Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940072272 sandostatin Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101227642A CN101618208B (zh) | 2008-06-30 | 2008-06-30 | 含微粉化重组人血管内皮抑制素缓释微球的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101227642A CN101618208B (zh) | 2008-06-30 | 2008-06-30 | 含微粉化重组人血管内皮抑制素缓释微球的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101618208A CN101618208A (zh) | 2010-01-06 |
CN101618208B true CN101618208B (zh) | 2012-07-04 |
Family
ID=41511737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008101227642A Active CN101618208B (zh) | 2008-06-30 | 2008-06-30 | 含微粉化重组人血管内皮抑制素缓释微球的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101618208B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103054809A (zh) * | 2011-12-22 | 2013-04-24 | 苏州雷纳药物研发有限公司 | 一种包含姜黄素微粒的高载药量缓释微球及其制备方法和用途 |
CN102895197B (zh) * | 2012-09-26 | 2014-10-15 | 上海交通大学 | 纳米颗粒混悬液包油-油包油制备微球的方法及缓释微球 |
CN108704137B (zh) * | 2018-08-02 | 2021-01-19 | 中国科学院过程工程研究所 | 载阿片受体部分激动剂缓释微球、其制备方法及应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1634570A (zh) * | 2004-09-29 | 2005-07-06 | 中国人民解放军第二军医大学 | 一种干扰素长效注射微球制剂的制备方法 |
CN1237072C (zh) * | 2000-05-22 | 2006-01-18 | 烟台荣昌生物工程有限公司 | 生产内皮抑制素的方法 |
CN1754570A (zh) * | 2004-09-28 | 2006-04-05 | 中国人民解放军军事医学科学院毒物药物研究所 | 含干扰素或其类似物的注射用缓释微球及其制备方法 |
CN1965809A (zh) * | 2005-11-16 | 2007-05-23 | 中国人民解放军军事医学科学院毒物药物研究所 | Lhrh拮抗剂类物质的注射用缓释微球及其制备方法 |
CN1981744A (zh) * | 2005-12-12 | 2007-06-20 | 上海医药工业研究院 | 石杉碱及其衍生物的注射用缓释微球的制备方法 |
-
2008
- 2008-06-30 CN CN2008101227642A patent/CN101618208B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1237072C (zh) * | 2000-05-22 | 2006-01-18 | 烟台荣昌生物工程有限公司 | 生产内皮抑制素的方法 |
CN1754570A (zh) * | 2004-09-28 | 2006-04-05 | 中国人民解放军军事医学科学院毒物药物研究所 | 含干扰素或其类似物的注射用缓释微球及其制备方法 |
CN1634570A (zh) * | 2004-09-29 | 2005-07-06 | 中国人民解放军第二军医大学 | 一种干扰素长效注射微球制剂的制备方法 |
CN1965809A (zh) * | 2005-11-16 | 2007-05-23 | 中国人民解放军军事医学科学院毒物药物研究所 | Lhrh拮抗剂类物质的注射用缓释微球及其制备方法 |
CN1981744A (zh) * | 2005-12-12 | 2007-06-20 | 上海医药工业研究院 | 石杉碱及其衍生物的注射用缓释微球的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101618208A (zh) | 2010-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2004259208B2 (en) | Method for the preparation of controlled release formulations | |
AU710347B2 (en) | Composition for sustained release of an agent | |
ES2283394T3 (es) | Kit para implantacion que contiene una fase de soporte y un disolvente. | |
RU2409348C2 (ru) | Лекарственные составы с контролируемым высвобождением, основанные на блок-сополимерах | |
CN103393632B (zh) | 一种卡巴他赛药物组合物及其制备方法 | |
CA2540771A1 (en) | Nanoparticulate therapeutic biologically active agents | |
CN102688198A (zh) | 多肽药物缓释微球制剂及其制备方法 | |
CN104622817B (zh) | 一种蛋白‑聚合物复合纳米载体及其制备方法 | |
US7087246B2 (en) | Controlled release preparation of insulin and its method | |
CN101797232B (zh) | 一种制备注射用小粒径重组人血管内皮抑制素缓释微粒的方法 | |
EP1561460B1 (en) | Nanoparticles for the administration of active ingredients, method of producing said particles and composition containing same | |
US6616949B2 (en) | Process for producing microparticles | |
CN101618208B (zh) | 含微粉化重组人血管内皮抑制素缓释微球的制备方法 | |
CN101396347B (zh) | 一种重组人血管内皮抑制素缓释微球的制备方法 | |
CN110237049A (zh) | 一种制备药物白蛋白纳米粒的方法 | |
CN104117056A (zh) | 载胎盘生长因子纳米粒及其制备方法和应用 | |
CN102793678B (zh) | 一种不含吐温的多烯紫杉醇注射剂的制备方法 | |
US6586011B2 (en) | Microencapsulated plasminogen activators | |
CN101428142B (zh) | 重组人血管内皮抑制素组合物缓释微球的制备方法 | |
CN101642559B (zh) | 含微粉化人血管内皮抑制素的药物组合物 | |
JP2010514679A (ja) | 制御放出組成物及び方法 | |
CN108619525B (zh) | 奈妥吡坦-mPEG-PLA纳米粒及其制备方法和用途 | |
JP3604782B2 (ja) | 持続性注射剤 | |
JP2004513706A (ja) | 微粒子の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU SIMCERE PHARMACEUTICAL CO., LTD. Effective date: 20150609 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150609 Address after: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Patentee after: JIANGSU SIMCERE PHARMACEUTICAL R & D Co.,Ltd. Patentee after: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. Address before: 210042 Xuanwu Avenue, Jiangsu, Nanjing, No. 699 -18 Patentee before: JIANGSU SIMCERE PHARMACEUTICAL R & D Co.,Ltd. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160504 Address after: 264006, No. 1, Heilongjiang Road, Yantai economic and Technological Development Zone, Shandong, Shandong, Yantai Patentee after: SHANDONG SIMCERE-MEDGENN BIOPHARMACEUTICAL Co.,Ltd. Patentee after: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. Address before: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Patentee before: JIANGSU SIMCERE PHARMACEUTICAL R & D Co.,Ltd. Patentee before: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 264006, No. 1, Heilongjiang Road, Yantai economic and Technological Development Zone, Shandong, Shandong, Yantai Co-patentee after: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. Patentee after: SHANDONG SIMCERE BIO-PHARMACEUTICAL Co.,Ltd. Address before: 264006, No. 1, Heilongjiang Road, Yantai economic and Technological Development Zone, Shandong, Shandong, Yantai Co-patentee before: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. Patentee before: SHANDONG SIMCERE-MEDGENN BIOPHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230703 Address after: 264006 No.1 Heilongjiang Road, Yantai Economic and Technological Development Zone, Yantai City, Shandong Province Patentee after: SHANDONG SIMCERE BIO-PHARMACEUTICAL Co.,Ltd. Address before: 264006 No.1 Heilongjiang Road, Yantai Economic and Technological Development Zone, Shandong Province Patentee before: SHANDONG SIMCERE BIO-PHARMACEUTICAL Co.,Ltd. Patentee before: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |